BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
Keywords: ABL; Abelson kinase; ALL; acute lymphoblastic leukemia; BCR; break clustering region; CML; chronic myeloid leukemia; DST; dasatinib; IMT; imatinib; NRT; nirotinib; Ph+; Philadelphia chromosome positive; TKI; tyrosine kinase inhibitor; Ph+ ALL; Imatinib-re